Jer‐Chia Tsai

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Association of Fluid Overload with Cardiovascular Morbidity and All-Cause Mortality in Stages 4 and 5 CKD

Yi‐Chun Tsai, Yi‐Wen Chiu, Jer‐Chia Tsai et al. · Clinical Journal of the American Society of Nephrology · 2014 · 155 citations · Full text

Association of Fluid Overload With Kidney Disease Progression in Advanced CKD: A Prospective Cohort Study

Yi‐Chun Tsai, Jer‐Chia Tsai, Szu‐Chia Chen et al. · American Journal of Kidney Diseases · 2013 · 114 citations

Glomerular Disease, Fluid Overload, Hemodialysis +11

Brachial-Ankle Pulse Wave Velocity and Rate of Renal Function Decline and Mortality in Chronic Kidney Disease

Szu‐Chia Chen, Jer‐Ming Chang, Wanchun Liu et al. · Clinical Journal of the American Society of Nephrology · 2011 · 113 citations · Full text